StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

Analysts at StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a report issued on Saturday. The firm set a “sell” rating on the medical technology company’s stock.

Several other research firms also recently issued reports on BIOL. Benchmark reaffirmed a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets decreased their price target on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd.

BIOLASE Price Performance

Shares of NASDAQ:BIOL opened at $0.02 on Friday. The business’s 50 day moving average price is $0.01 and its 200-day moving average price is $0.05. BIOLASE has a 1 year low of $0.02 and a 1 year high of $1.94. The firm has a market capitalization of $581,281.80, a price-to-earnings ratio of 0.00 and a beta of 0.67.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.